What makes CPPD unique compared to other crystal arthropathies?
▼
CPPD disease differs from gout in several fundamental ways. The crystals involved are calcium pyrophosphate (CPP) rather than monosodium urate, they have positive birefringence on polarized microscopy (versus gout's negative birefringence), they form in fibrocartilage and hyaline cartilage rather than predominantly in the soft tissue, and they have distinct predilection for the knee, wrist, and pubic symphysis rather than the 1st MTP joint. CPPD also tends to affect older adults and is strongly associated with metabolic conditions like hyperparathyroidism and hemochromatosis, which don't predispose to gout. These criteria are the first-ever validated classification criteria for CPPD and were published in 2023 after a four-year multinational development process.
Why does 1st MTP joint involvement score -6 points?
▼
The 1st metatarsophalangeal joint (big toe) is the classic site for gout - the hallmark of gout flares (podagra). While CPPD can theoretically affect any joint, involvement of the 1st MTP is atypical for CPPD and much more suggestive of gout. The expert committee determined that this feature should actively lower the probability of CPPD classification because it points toward an alternative diagnosis. This negative weighting is one of the most distinctive features of the CPPD criteria, where clinical expertise in crystal arthropathy informed that some findings are anti-evidence, not just neutral.
Why does negative synovial fluid analysis score only -1 or -7, not eliminate the diagnosis?
▼
CPP crystals are notoriously difficult to identify - they are often weakly or non-birefringent (making polarizing microscopy unreliable) and can be sparse in the fluid even during active disease. The 2023 criteria deliberately treat negative synovial fluid as a 'silver standard' rather than a gold standard. A single negative analysis subtracts only 1 point, recognizing that false negatives are common due to technical limitations. Even two negative analyses (which subtracts 7 points) does not eliminate classification if the remaining features are strongly positive, because the technical challenges of CPP crystal identification are well established.
What is crowned dens syndrome and why does it qualify as a sufficient criterion?
▼
Crowned dens syndrome (CDS) is a manifestation of CPPD involving the atlanto-axial (C1/C2) joint, where CPP crystal deposits form a 'crown' around the odontoid process. It presents with acute or subacute severe upper neck pain, elevated inflammatory markers (ESR, CRP), limited cervical rotation, and often fever - mimicking meningitis or polymyalgia rheumatica. The imaging hallmark is linear calcific deposits (less dense than cortical bone) in the transverse retro-odontoid ligament on CT, often appearing as two parallel lines in axial views. DECT can confirm CPP crystal composition (dual-energy index 0.016-0.036). When both the clinical features AND characteristic imaging are present simultaneously, this combination is considered highly specific for CPPD, qualifying it as a sufficient criterion alongside synovial fluid crystal confirmation.
Why do imaging domains carry so much weight - nearly half the 100-point total?
▼
Imaging evidence of CPP crystal deposition in peripheral joints (domains G and H) can contribute up to 41 points combined (16 for symptomatic joint + 25 for 4 or more joints with CPPD). Together with domain F (OA pattern), imaging accounts for up to 48 of 100 points. This reflects expert consensus that imaging evidence of CPP crystal deposition is the central construct for CPPD classification when laboratory crystal confirmation is unavailable. The criteria were developed during an era when advanced imaging (US, CT, DECT) had greatly improved detection of CPPD beyond what conventional X-ray could show. The heavy weighting for multiple joint involvement also incentivizes systematic imaging, which increases diagnostic yield.
When should I image bilateral joints to maximize scoring accuracy?
▼
Domain H (number of peripheral joints with CPPD on any imaging) rewards identification of multiple affected joints - with a significant score jump from 16 points for 1 joint to 23 for 2-3 joints and 25 for 4 or more. Bilateral imaging of the knees and wrists - the two most commonly affected sites - can potentially identify CPPD in both sides even when symptoms are unilateral. The criteria steering committee considered mandating bilateral imaging of standardized joints but decided against it for feasibility reasons, especially in lower-resource settings. However, clinicians should be aware that more systematic imaging increases the potential score and classification probability.
How should CPPD coexisting with osteoarthritis be handled?
▼
CPPD frequently coexists with osteoarthritis - this is explicitly acknowledged in the criteria framework. The exclusion criterion only blocks classification when all symptoms are more likely explained by the alternative condition. If a patient has OA but also has inflammatory episodes that cannot be fully attributed to OA, CPPD classification may still proceed. Importantly, articular cartilage CPP crystal deposition found in patients with end-stage OA where all symptoms are explained by OA does not qualify as a sufficient criterion. This nuance prevents misclassification of incidental CPP deposits in OA patients who do not have symptomatic CPPD disease.
What metabolic conditions predispose to CPPD and how are they screened?
▼
The metabolic conditions included in domain D each cause CPPD through different mechanisms. Primary hyperparathyroidism causes elevated calcium, which increases CPP crystal precipitation. Hereditary hemochromatosis leads to iron deposition in cartilage that disrupts pyrophosphatase enzymes. Hypomagnesemia (including Gitelman syndrome, a tubular transport disorder) allows excess pyrophosphate, as magnesium is needed for pyrophosphatase activity. Hypophosphatasia is a deficiency of tissue-nonspecific alkaline phosphatase, an enzyme that breaks down extracellular pyrophosphate - its deficiency leads to pyrophosphate accumulation. Screening should include serum calcium/PTH, ferritin/transferrin saturation, serum magnesium, and alkaline phosphatase, especially in patients under 55 or with extensive polyarticular chondrocalcinosis.
What are the specific OA patterns that score points in domain F, and why these joints?
▼
Domain F recognizes two distinct radiographic OA patterns characteristic of CPPD. Bilateral radiocarpal joint OA (2 points) is unusual in typical mechanical OA and suggests CPPD-associated cartilage disease. The higher-weighted pattern (7 points) includes at least two of: scaphotrapeziotrapezoid (STT) joint OA without 1st carpometacarpal joint involvement (this specific pattern - sparing the 1st CMC - distinguishes CPPD-associated OA from plain thumb base OA), 2nd MCP joint OA, or 3rd MCP joint OA. These patterns reflect how CPPD preferentially involves central wrist joints and the radial MCP joints, creating a recognizable hand/wrist OA pattern that is atypical for primary OA.
Can this calculator be used to diagnose CPPD in clinical practice?
▼
No - like all ACR/EULAR classification criteria, the 2023 CPPD criteria are specifically designed for research classification, not clinical diagnosis. The goal is to identify a relatively homogeneous group of patients with well-characterized CPPD for inclusion in clinical studies - not to capture all patients who may have CPPD clinically. Classification criteria prioritize specificity and standardization, which means some patients with true CPPD may not meet the threshold, and some patients near the threshold may require additional clinical judgment. For individual patient care, clinical diagnosis of CPPD remains based on the full clinical picture, synovial fluid analysis, and appropriate imaging, informed by rheumatologic expertise.
What is the difference between acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and OA with CPPD?
▼
The 2011 EULAR recommendations established three main clinical phenotypes. Acute CPP crystal arthritis (previously 'pseudogout') presents as a self-limiting acute mono- or oligoarthritis typically of the knee or wrist, resembling gout, often with fever and markedly elevated inflammatory markers. Chronic CPP crystal inflammatory arthritis presents as ongoing synovitis - either persistent or recurrent - mimicking rheumatoid arthritis; patients may have morning stiffness and elevated ESR/CRP. OA with CPPD involves CPP crystal deposition in the context of degenerative joint disease with the CPPD-associated OA pattern. These phenotypes can coexist in the same patient over time. The 2023 classification criteria accommodate all phenotypes and are scored based on the patient's total disease experience, not just the current episode.
What is the significance of the score threshold >56 versus other possible thresholds?
▼
The threshold of >56 was selected through ROC curve analysis and expert consensus review of 30 patient profiles to balance sensitivity and specificity. In the derivation cohort, a score of ≥57 gave 87.9% specificity and sensitivity of 92.2%. The steering committee reviewed 'borderline' cases just below the threshold - including a single wrist flare with age >60 and wrist chondrocalcinosis (scoring 56), a knee flare under age 60 with knee chondrocalcinosis (scoring 53), and a non-inflammatory case with bilateral radiocarpal OA and bilateral wrist chondrocalcinosis (scoring 50) - and agreed these cases had sufficient uncertainty that they should not classify. The >56 threshold (meaning 57 or higher) was validated in an independent cohort of 413 patients, where it achieved 99.2% sensitivity and 92.5% specificity.